Private Placement

Once mired in debt, Castellum has secured over $170M in prime contracts, signaling a dramatic resurgence in the competitive federal defense market.

Beyond the press release: How two strategic hires signal Plus Therapeutics' aggressive push to commercialize its CNSide platform and capture a $6B market.

With a critical $1.74M lifeline, Northstar Clean Technologies is racing to prove its shingle recycling tech can be a profitable circular economy champion.

With stellar clinical data for its TERN-701 drug, Terns is raising massive capital to challenge Novartis and reshape the multi-billion-dollar CML market.

With backing from the US and Australia, a titanium giant is pivoting to critical minerals, a strategic move challenging global supply chain dominance.

Ashika Investment Managers launches a fund to capture India's next growth wave. Can its disciplined, data-driven strategy unlock value in a volatile market?

Reborn Coffee touts a tech-driven global expansion, but a looming Nasdaq delisting and deep financial losses paint a much more complicated picture.

A massive 320 MWh battery project in Belgium reveals how strategic investments in energy storage are becoming the ultimate luxury: grid stability and sustainability.

Advanced chip packaging is the unsung hero of the AI revolution, with a market set to explode. But can the industry sustain its billion-dollar habit?

As Thailand braces for another toxic smog season, air purifier giant Levoit deploys a timely strategy to capture a market born from a public health crisis.

A Japanese chemical plant's new AI-powered microgrid reveals how firms are using renewables not just for ESG, but as a defense against disaster and grid failure.

Guangdong Jiaying Pharma is leveraging its unique Hakka heritage to enter the global market. But can ancient wisdom navigate modern regulatory and corporate hurdles?

A deep dive into 22 Fulton Street, where complex finance, green design, and affordable housing converge to reshape Newark's skyline and its community.

New clinical data reveals a breakthrough 'off-the-shelf' cell therapy that could treat severe autoimmune diseases by re-engineering cellular identity.

The ADA’s new standards push for tech from day one and holistic care, but can the system deliver this innovative future to every patient?

A sleepy cat GIF with 2.4B views is now a children's book. We analyze the business strategy behind turning viral fame into a publishing success story.

John Crowley, who fought to save his own children, will now shape the future of medicine as he headlines the landmark 2026 MDA conference.

After crossing $1B in assets, a community bank adds a healthcare PE expert to its board. This is more than a hire—it's a new strategy for growth.

Newron launches a pivotal US trial for its novel schizophrenia drug, evenamide, aiming to help millions who don't respond to current treatments.

A Swiss firm claims a CHF 480M raise and a $300M tech fund, but a closer look reveals a company with virtually no verifiable corporate footprint.